SLNO - Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $2.76B
- P/E Ratio
- 28.75
- Beta
- -2.22
- 52-Week Range
- 29.43-90.3199
- CEO
- Anish Bhatnagar
- Employees
- 115
- IPO Date
- Nov 13, 2014
- Exchange
- NASDAQ
SLNO Options Snapshot
Options pricing data for SLNO is refreshed daily after the close. When listed contracts exist, this page surfaces the latest at-the-money implied volatility, max pain strike, dealer gamma exposure (GEX), and 25-delta skew. Listed contracts and live snapshots appear once the options chain has been published by the exchange for the most recent session.
What This Page Covers
The SLNO overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.